Document Type
Article
Author ORCID Identifier
Menny M. Benjamin https://orcid.org/0000-0002-0212-3405
George S. Hanna https://orcid.org/0000-0001-7616-064X
Cody F. Dickinson https://orcid.org/0000-0003-1318-4438
Yeun-Mun Choo https://orcid.org/0000-0001-9891-5898
Xiaojuan Wang https://orcid.org/0000-0001-5559-6997
Jessica A. Downs-Bowen https://orcid.org/0000-0002-7472-033X
Ramyani De https://orcid.org/0000-0001-5534-0705
Raymond F. Schinazi https://orcid.org/0000-0002-6688-3614
Sarah E. Nielson https://orcid.org/0009-0009-8070-4350
Joan M. Hevel https://orcid.org/0000-0002-9559-4635
Pankaj Pandey https://orcid.org/0000-0001-9128-8254
Robert J. Doerksen https://orcid.org/0000-0002-3789-1842
Danyelle M. Townsend https://orcid.org/0000-0003-4679-1891
Lucas Bialousow https://orcid.org/0000-0003-1126-8670
Journal/Book Title/Conference
Molecules
Volume
29
Issue
21
Publisher
MDPI AG
Publication Date
10-28-2024
Journal Article Version
Version of Record
First Page
1
Last Page
17
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Abstract
The design and synthesis of antiviral compounds were guided by computationally predicted data against highly conserved non-structural proteins (Nsps) of the SARS-CoV-2 coronavirus. Chromenephenylmethanone-1 (CPM-1), a novel biphenylpyran (BPP), was selected from a unique natural product library based on in silico docking scores to coronavirus Nsps with high specificity to the methyltransferase protein (2′ -O-MTase, Nsp10–16), which is responsible for viral mRNA maturation and host innate immune response evasion. To target the 2′ -O-MTase, CPM-1, along with intermediate BPP regioisomers, tetrahydrophenylmethanones (TPMs), were synthesized and structurally validated via nuclear magnetic resonance (NMR) data and DP4+ structure probability analyses. To investigate the activity of these BPPs, the following in vitro assays were conducted: SARS-CoV-2 inhibition, biochemical target validation, mutagenicity, and cytotoxicity. CPM-1 possessed notable activity against SARS-CoV-2 with 98.9% inhibition at 10 µM and an EC50 of 7.65 µM, as well as inhibition of SARS-CoV-2’s 2′ -O-MTase (expressed and purified) with an IC50 of 1.5 ± 0.2 µM. In addition, CPM-1 revealed no cytotoxicity (CC50 of >100 µM) or mutagenicity (no frameshift or base-pair mutations). This study demonstrates the potential of computational modeling for the discovery of natural product prototypes followed by the design and synthesis of drug leads to inhibit the SARS-CoV-2 2′ -O-MTase.
Recommended Citation
Benjamin, M.M.; Hanna, G.S.; Dickinson, C.F.; Choo, Y.-M.; Wang, X.; Downs-Bowen, J.A.; De, R.; McBrayer, T.R.; Schinazi, R.F.; Nielson, S.E.; et al. Cannabinoid-Inspired Inhibitors of the SARS-CoV-2 Coronavirus 2′-O-Methyltransferase (2′-O-MTase) Non-Structural Protein (Nsp10–16). Molecules 2024, 29, 5081. https://doi.org/10.3390/molecules29215081